Tag Archives: Aviv Regev

Roche to Acquire Poseida Therapeutics, Advancing Leadership in Cell Therapy Innovation

(IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies, for $9.00 per share in cash, totaling approximately $1 billion. Poseida stockholders may also receive up to $4.00 per share … Read the full press release